Jakob Lindberg, Oncopeptides CEO

Months af­ter pulling on­ly drug from US, On­copep­tides takes back with­draw­al re­quest — but stays mum on why

What hap­pens when you pull a re­quest to pull your drug from the mar­ket?

On­copep­tides is try­ing to find out, re­veal­ing late Fri­day that it has con­tact­ed the FDA and re­scind­ed a let­ter it sent back in Oc­to­ber, re­quest­ing vol­un­tary with­draw­al of the NDA of its mul­ti­ple myelo­ma drug, Pepax­to, in the US — the on­ly place where it’s ap­proved.

The Stock­holm-based biotech trig­gered a ma­jor melt­down with the an­nounce­ment back in Oc­to­ber, as the with­draw­al would force it to close its US and EU busi­ness units and en­act sig­nif­i­cant lay­offs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.